Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company, is set to host a webinar to present findings from its BEACON study in chronic spontaneous urticaria, along with preliminary data from the ETESIAN study in asthma, on December 2, 2025.
-- BEACON is a placebo-controlled Phase 1b/2a trial evaluating multiple ascending doses of subcutaneous Briquilimab as a therapy for adult patients with moderate to severe chronic spontaneous urticaria despite treatment with high-dose antihistamines.
Results reported in July this year from the BEACON trial showed that Briquilimab produced rapid and strong disease control in the 240 mg and 360 mg single-dose groups. Overall, 8 of 9 participants (89%) achieved a complete response, and 7 of 9 (78%) had a clinical response by week 2.
In addition, in the open-label extension, BEACON participants receiving 180 mg every 8 weeks demonstrated robust clinical efficacy - with 8 of 11 (73%) participants achieving a complete response at 12 weeks.
-- ETESIAN is a phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma. Initiated last December, this study is expected to enroll approximately 30 patients across as many as 7 sites in Canada.
However, due to a drug product lot issue, the company halted the ETESIAN study and paused development in asthma earlier this year.
JSPR closed Monday's trading at $1.72, down 6.52%. In overnight trading, shares are trading 16.27% higher at $2 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.